论文部分内容阅读
目的 观察吉西他滨 (健择 )联合顺铂 /草酸铂 (GP/GEM OX方案 )治疗晚期不能手术或手术后复发的胰腺癌患者的疗效与不良反应。方法 2 8例患者分别给予GP或GEM OX方案 2～ 13周期。按WHO标准评定疗效和不良反应。结果 2 6例可评价疗效 ,无一例完全缓解 (CR ,0 % ) ,部分缓解 (PR) 7例(2 6 9% ) ,稳定 (SD) 10例 (38 5 % ) ,进展 (PD) 9例 (34 6 % )。可评价临床受益反应 (CBR) 2 7例 ,有效率为70 4 % (19/ 2 7)。中位疾病进展时间为 4 2个月 ,中位生存时间为 9 3个月。结论 健择联合顺铂 /草酸铂是治疗晚期胰腺癌患者的安全有效方案 ,并能较好改善疾病相关症状 ,毒副反应可以耐受。
Objective To observe the efficacy and side effects of gemcitabine combined with cisplatin / oxaliplatin (GP / GEM OX) in the treatment of patients with advanced pancreatic cancer who can not undergo surgery or postoperative recurrence. Methods Twenty-eight patients were given GP or GEM OX regimen for 2 to 13 cycles, respectively. According to the WHO standard assessment of efficacy and adverse reactions. RESULTS: Twenty-six patients were evaluated for complete response (CR, 0%), partial response (PR) in 7 patients (269%), stable (SD) in 10 patients Example (34 6%). The clinical benefit response (CBR) was evaluated in 27 patients with an effective rate of 70.4% (19/27). The median time to progression was 42 months and the median survival time was 93 months. Conclusions Gemcitabine combined with cisplatin / oxaliplatin is a safe and effective treatment for patients with advanced pancreatic cancer, and can better improve the disease-related symptoms, toxic and side effects can be tolerated.